Colorectal cancer

Selected publications

Strømme JM, Johannessen B, and Skotheim RI (2023). Deviating alternative splicing as a molecular subtype of microsatellite stable colorectal cancer. JCO Clin. Cancer Inform. 7: e2200159

Sveen A, Johannessen B, Eilertsen IA, Røsok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O, Bjørnbeth BA, Skotheim RI, Nesbakken A, and Lothe RA (2021). The expressed mutational landscape of microsatellite stable colorectal cancers. Genome Med. 13(1): 142

Sveen A*, Johannessen B*, Tengs T*, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, and Lothe RA (2017). Multilevel genomics of colorectal cancers with microsatellite instability - clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Med. 9(1): 46 *Equal contribution

Hoff AM*, Johannessen B*, Alagaratnam S, Zhao S, Nome T, Løvf M, Bakken AC, Hektoen M, Sveen A, Lothe RA, and Skotheim RI (2015). Novel RNA-variants in colorectal cancers. Oncotarget 6(34): 36587-36602 *Equal contribution

Bruun J, Kolberg M, Ahlquist TC, Røyrvik E, Nome T, Leithe E, Lind GE, Merok MA, Rognum TO, Bjørkøy G, Johansen T, Johansen T, Lindblom A, Sun XF, Svindland A, Liestøl K, Nesbakken A, Skotheim RI, and Lothe RA (2015). Regulator of chromosome condensation 2 identifies high-risk patients with both major phenotypes of colorectal cancer. Clin. Cancer Res. 21(16): 3759-3770

Løvf M, Nome T, Bruun J, Eknæs M, Bakken AC, Mpindi JP, Kilpinen S, Rognum TO, Nesbakken A, Kallioniemi O, Lothe RA, and Skotheim RI (2014). A novel transcript, VNN1-AB, as a biomarker for colorectal cancer. Int. J. Cancer 135(9): 2077-2084

Nome T*, Hoff AM*, Bakken AC, Rognum TO, Nesbakken A, and Skotheim RI (2014). High frequency of fusion transcripts involving TCF7L2 in colorectal cancers: Novel fusion partner and splice variants. PLoS One 9(3): e91264 *Equal contribution

Nome T, Thomassen GOS, Bruun J, Ahlquist TC, Bakken AC, Hoff AM, Rognum T, Nesbakken A, Lorenz S, Sun J, Barros-Silva JD, Lind GE, Myklebost O, Teixeira MR, Meza-Zepeda LA, Lothe RA, and Skotheim RI (2013). Common fusion transcripts identified in colorectal cancer cell lines by high throughput RNA sequencing. Transl. Oncol. 6(5): 546-553

Cekaite L, Rantala JK, Bruun J, Guriby M, Ågesen TH, Danielsen SA, Lind GE, Nesbakken A, Kallioniemi O, Lothe RA*, and Skotheim RI* (2012). MiR-9, -31 and miR-182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia 14(9): 868-881; *Shared senior authors

Sveen A, Ågesen TH, Nesbakken A, Meling GI, Rognum TO, Liestøl K, Skotheim RI, and Lothe RA (2012). ColoGuidePro: A prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin. Cancer Res. 18(21): 6001-6010

Ågesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skotheim RI, and Lothe RA (2012). ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut 61: 1560-1567

Sveen A, Bakken AC, Ågesen TH, Lind GE, Nesbakken A, Nordgård O, Brackmann S, Rognum TO, Lothe RA, and Skotheim RI (2012). The exon-level biomarker SLC39A14 has organ confined cancer specificity in colorectal cancer. Int. J. Cancer 131: 1479-1485

Ågesen TH, Berg M, Clancy T, Thiis-Evensen E, Cekaite L, Lind GE, Nesland JM, Bakka A, Mala T, Hauss HJ, Fetveit T, Hovig E, Nesbakken A, Lothe RA, and Skotheim RI (2011). CLC and IFNAR1 are differentially expressed and a global immunity score is distinct between early and late onset colorectal cancer. Genes and Immunity 12(8): 653-662

Sveen A, Ågesen TH, Nesbakken A, Rognum TO, Lothe RA, and Skotheim RI (2011). Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. Genome Medicine 3(5): 32